Biodesix (NASDAQ:BDSX – Get Free Report) will likely be issuing its quarterly earnings data after the market closes on Monday, March 3rd. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $19.92 million for the quarter. Parties interested in registering for the company’s conference call can do so using this link.
Biodesix Price Performance
Shares of NASDAQ:BDSX opened at $0.79 on Friday. The company has a current ratio of 3.40, a quick ratio of 3.40 and a debt-to-equity ratio of 1.30. Biodesix has a 1 year low of $0.75 and a 1 year high of $2.04. The business has a fifty day simple moving average of $1.14 and a 200 day simple moving average of $1.43. The firm has a market cap of $115.36 million, a price-to-earnings ratio of -2.03 and a beta of 1.06.
Insider Buying and Selling at Biodesix
In other Biodesix news, CEO Scott Hutton sold 83,660 shares of the firm’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $0.92, for a total transaction of $76,967.20. Following the transaction, the chief executive officer now directly owns 701,947 shares in the company, valued at $645,791.24. This trade represents a 10.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 128,702 shares of company stock worth $118,406 over the last three months. Corporate insiders own 69.20% of the company’s stock.
Biodesix Company Profile
Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.
Featured Stories
- Five stocks we like better than Biodesix
- Insider Buying Explained: What Investors Need to Know
- Analysts Lift Archer Aviation Stock Despite Earnings Miss
- Stock Dividend Cuts Happen Are You Ready?
- 5 Best Gold ETFs for March to Curb Recession Fears
- How to Capture the Benefits of Dividend Increases
- 3 Stocks for Your Watchlist: Unlocking Tomorrow’s Winners Today
Receive News & Ratings for Biodesix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodesix and related companies with MarketBeat.com's FREE daily email newsletter.
